Among the DEPs, six proteins that had been reported to be related to the prognosis of AML and other cancers and had relative higher FC ratios by comparison (Table S2), including FH (poor-risk vs intermediate-risk, FC = 1.36) [18], GLUL (poor-risk vs favorable-risk, FC = 2.06) [19], LTF (poor-risk vs favorable-risk, FC = 3.15) [20], ENO1 (poor-risk vs intermediate-risk, FC = 1.29) [21], HADH (poor-risk vs favorable-risk, FC = 1.74) [22], and IDH2 (poor-risk vs favorable-risk, FC = 2.25) [18,23], were selected as potent candidates for validation. The gene discussed is HADH; the disease is acute myeloid leukemia.